Even if more clinical trials are needed to support PAIP2 expression as a protective factor for OS, PPS and DMFS in STAD patients, it also shows the potential value of PAIP2 as a prognostic biomarker for breast cancer patients. Here, PAIP2 is linked to breast carcinoma.